Toxicity of intravesical BCG and its management in patients with superficial bladder tumors

Cancer

Volumn 60, Issue 3, 1987, Pages 326-333

  Orihuela, Eduardo ^a   Herr, Harry W ^a   Pinsky, Carl M ^a   Whitmore, Willet F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADVERSE DRUG REACTION; ARTHRITIS; BLADDER; BLADDER CARCINOMA; BLOOD AND HEMOPOIETIC SYSTEM; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYSTITIS; DRUG ADMINISTRATION; DRUG THERAPY; DRUG TOXICITY; FEVER; GASTROINTESTINAL TOXICITY; GRANULOMA; HUMAN; IMMUNOTHERAPY; INFLUENZA; INTOXICATION; JOINT; LEUKOCYTOSIS; LIVER TOXICITY; LUNG INFILTRATE; LUNG TOXICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESPIRATORY SYSTEM; THERAPY;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; BLADDER NEOPLASMS; CYSTITIS; CYSTOSCOPY; FEMALE; FEVER; HUMAN; IMMUNOTHERAPY; MALE; MIDDLE AGE;

EID: 0023228973     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19870801)60:3<326::AID-CNCR2820600309>3.0.CO;2-5     Document Type: Article

References (39)

1. Intracavitary bacillus Calmette Guerin in the treatment of superficial bladder tumor
2. Experience with bacillus Calmette‐Guerin in patients with superficial bladder carcinoma
3. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette‐Guerin
4. Effect of intravesical bacillus Calmette‐Guerin (BCG) on carcinoma in situ of the bladder
5. Experience with intravesical bacillus Calmette‐Guerin therapy of superficial bladder tumors
6. Bacillus Calmette‐Guerin immunotherapy of superficial bladder cancer
7. Long‐term results and complications of intracavitary bacillus Calmette‐Guerin therapy for bladder cancer
8. Bacillus Calmette‐Guerin (BCG) in the treatment of transitional cell carcinoma (TCC) of the bladder (Abstr)
9. BCG vs. Adriamycin in the treatment of transitional call carcinoma in situ: A Southwest Oncology Group study (abstr)
10. Complications of BCG immunotherapy in patients with bladder cancer (abstr)
11. Skin tests
12. BCG vaccine and its derivatives: Potential, practical considerations, and precautions in human cancer immunotherapy
13. Immunopathology
14. Treatment of malignant melanomas by intratumoral injection of BCG
15. Effect of BCG on delayed hypersensitivity responses of patients with neoplastic disease
16. Complications of BCG immunotherapy in patients with cancer
17. BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses
18. Disseminated BCG disease associated with immunotherapy by scarification in acute leukemia
19. Immunotherapy of melanoma with BCG: Two fatalities following intralesional injection
20. Use of BCG in the treatment of human neoplasms: A review
21. Complications of BCG vaccination in neoplastic disease
22. Immunotherapy with BCG administered by scarification: Standardization of reactions and management of side effects
23. Pulmonary granulomas in duced by BCG
24. Clinical and immunological studies of disseminated BCG infections
25. Complications of bacillus Calmette‐Guerin immunotherapy in 1,278 patients with bladder cancer
26. Adjuvant immunotherapy in superficial bladder cancer
27. Treatment of carcinoma in situ of the bladder with BCG: A phase II trial
28. Treatment of residual, non‐infiltrating bladder cancer with bacillus Calmette‐Guerin
29. Bacillus Calmette‐Guerin for superficial transitional cell carcinoma of the bladder
30. Long‐term effect of intravesical bacillus Calmette‐Guerin on flat carcinoma in situ of the bladder
31. Correction for BCG dosage in bladder cancer treatment (letter)
32. Intravesical bacillus Calmette‐Guerin therapy and associated granulomatous renal masses
33. Immunocompetence of patient with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocytic function
34. Maintenance intravesical bacillus Calmette‐Guerin in patients with recurrent superficial carcinoma of the urinary bladder (abstr)
35. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette‐Guerin
36. Bacillus Calmette‐Guerin immunotherapy for bladder cancer
37. Two courses of intravesical bacillus Calmette‐Guerin for transitional cell carcinoma of the bladder
38. Intravesical administration of bacillus Calmette‐Guerin in patients with recurrent superficial carcinoma of the urinary bladder: Report of a prospective, randomized trial